Mayo Clinic - Scottsdale
Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-10-06 | NCT07226843 | |
| PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-25 | NCT01723774 | |
| A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | Hemic and Lymphatic Diseases, Neoplasms by Site, VEXAS syndrome, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, myelodysplastic syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-15 | NCT06782373 | |
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Recruiting | Phase 2 / Phase 3 | 2026-09-03 | NCT03013998 | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04285086 | |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-07-15 | NCT06679985 | |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-06-22 | NCT05696626 | |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Adenomatous Polyps, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cronkhite-Canada syndrome, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenoma, classic familial adenomatous polyposis, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, intestinal disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-05 | NCT05552755 | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, angiosarcoma, breast cancer, breast disorder, breast neoplasm, neoplasm, sarcoma, skin disorder, triple-negative breast carcinoma, vascular cancer | Recruiting | Phase 2 | 2026-05-06 | NCT01042379 |